PD-MIND in a nutshell

Parkinson’s disease with mild cognitive impairment (PD-MCI) is a common condition which has important clinical consequences. There is currently no treatment available for Parkinson’s. Thus, there is an unmet clinical need to treat PD-MCI.

The PD-MIND (Parkinson’s disease with mild cognitive impairment treated with nicotinic agonist drug) project aims to develop a treatment for PD-MCI, by means of a clinical study involving a potential new drug thought to improve memory, learning and thought processes.

Study Design

PD-MIND is a phase 2a, randomized, double-blind, placebo-controlled, parallel-group designed study. It is an international multi-centre study with 10 study sites in Europe: UK, Italy, Germany, Czech Republic and Norway. 160 individuals with PD-MCI will be recruited and randomised: 80 in an active (AZD0328) group and 80 in a control (placebo) group. A subset of 90 participants will have  MRI scans taken at their study entry and exit in order to compare pictures of the brain before and after taking study medication.

Share this page…